口服氟尿嘧啶类制剂治疗进展期结直肠癌的现状与进展  

Recent status and progression of oral fluorouracil in treatment of advanced colorectal cancer

作　　者：赵文英[1] 陈景华[1] 

机构地区：[1]皖南医学院弋矶山医院肿瘤内科,安徽芜湖241001

出　　处：《临床肿瘤学杂志》2013年第11期1049-1054,共6页Chinese Clinical Oncology

摘　　要：氟尿嘧啶类化疗药物在结直肠癌治疗中占有非常重要的地位,口服氟尿嘧啶类制剂包括优福啶、脱氧氟尿苷、卡培他滨、替吉奥等,与传统氟尿嘧啶(5-FU)相比具有高效、低毒、应用方便等优点,其临床应用也越来越广泛。本文回顾分析了5-FU的作用机制以及口服氟尿嘧啶类制剂的研发情况,并就口服氟尿嘧啶类制剂治疗进展期结直肠癌的现状与进展作一综述。Fluorouracil is important in the treatment of colorectal cancer. Compared with traditional 5-fluorouracil, the oral fluorouracil（inclnding UFT, doxifluridine, capecitabine, S-l, etc） has numerous advantages such as： high efficiency, low toxicity, ease of application and so on. It is widely used in clinical. This review analyzes the mechanism of 5-FU and the development of oral fluorouracil, and the recent status and progression of oral fluorouraeil in treatment of advanced coloreetal cancer.

关 键 词：优福啶 脱氧氟尿苷 卡培他滨 替吉奥 进展期结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]